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Peripheral microvascular impairment in systemic sclerosis (SSc) may be easily detected and scored in a safe noninvasive way
by nailfold videocapillaroscopy (NVC). The paper highlights clinical conditions related to SSc in which NVC may represent an
outcome measure of therapeutical interventions, by elaborating on their already assessed relationship with the NVC patterns
and eventually scores. The 3 important biological/clinical conditions are: the positivity for SSc-speciﬁc serum autoantibodies,
the presence of SSc skin digital ulcers (DUs) and of pulmonary arterial hypertension (PAH) SSc associated. In conclusion, to the
questionifcapillaroscopy (NVC)may representin SScan outcomemeasureforclinical trialson theperipheral vasculopathy, based
on the growing evidence and our detailed studies, the answer is positive. Recent therapeutic trials in SSc are conﬁrming this role,
and the experience is growing rapidly.
1.Introduction
Systemic sclerosis (SSc) is characterized by early and
persistent microvascular impairment leading to functional
Raynaud’s phenomenon (RP) and clinical manifestations
(i.e., digital ulcers, pulmonary arterial hypertension, etc.)
(Figure 1)[ 1, 2].
Digital ulcers in SSc are considered to be related to
tissue ischemia following several processes, including at the
beginning persistent vasospasm (RP), but in the progression
of the disease also to intimal ﬁbroproliferation, tissue
ﬁbrosis, and thrombosis of digital arteries [3].
Progressive deﬁciency in vasodilatory capacity of the
vessels and tissue ﬁbrosis is proposed as a mechanism of
the persistent vascular spasm; however, the mechanism of
endothelial injury is still unclear [4].
The assessment of vascular involvement is still a matter
of study, and several noninvasive techniques have been
proposed. Peripheral microvascular impairment in SSc may
be easily and safely detected by nailfold videocapillaroscopy
(NVC). The morphological capillary abnormalities in SSc
have been classiﬁed in 3 validated patterns (early, active, and
late) of microangiopathy by NVC and scored (Figure 2)[ 5–
7].
NVC may partially observe the column of red blood cells
moving inside the capillary, but the technique does not allow
measurement of the blood ﬂow.
Laser Doppler ﬂowmetry (LDF) is the best non invasive
and safe technique to assess and to measure the blood
perfusion at peripheral sites [8, 9].
Blood ﬂow has been found to be reduced in patients
with SSc, compared with healthy subjects and patients with
primary RP. Patients with SSc showing the late NVC pattern
of microangiopathy have a signiﬁcantly lower ﬁnger blood
perfusion (FBP) than patients with the active and early NVC
patterns (P<. 05) [10].
The question today is if capillaroscopy (and eventually
LDF) may represent an outcome measure for clinical trials
on the peripheral vasculopathy in SSc.
WewillanalyzeclinicalconditionsrelatedtoSScinwhich
NVC may represent an outcome measure by considering
their already assessed relationship with the NVC patterns2 International Journal of Rheumatology
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Figure 1: Hands of a patient with early systemic sclerosis suﬀering
from secondary Raynaud’s phenomenon.
and/or eventually scores. The 3 important biological/clinical
conditions are: the SSc-speciﬁc serum autoantibodies, the
SSc skin digital ulcers (DUs), and the pulmonary arterial
hypertension (PAH) associated to SSc.
2.SerumAutoantibodiesandNVC
SScischaracterizedby serumautoantibodies, including anti-
centromere (anti-CENP-B), anti-Th/To, antitopoisomerase I
(anti-topo I), and anti-RNA polymerase I/III (anti RNAP
III). Together, these markers account for almost 85% of
autoantibodies speciﬁc for SSc and show a predictive value
for clinical evaluation and prognosis [11, 12].
Anti-CENP-B and anti-topo I are known predictors of
progression from isolated RP to SSc [13]. However, until
recently,manyofthestudiesonthesigniﬁcanceofexpression
of these antibodies in SSc have been limited by small sample
sizes, incorrect classiﬁcation of patients with manifestations
of connective tissue disorders as having primary RP, use of
varyingdeﬁnitionsofsubsetsofpatients,lackofstandardised
methods for determining antinuclear antibodies, omission
of tests for anti-Th/To and anti-RNAP III antibodies, and
absence of multivariable analyses.
Antiendothelial cell antibodies (AECAs) are a heteroge-
neous class of antibodies whose role in the pathogenesis of
autoimmune diseases with vascular involvement has been
extensively studied and are present in the serum samples
of many patients with SSc (22–86%) but are not SSc
speciﬁc [14]. Even if, among the demonstrated clinical
associations, lung and peripheral vascular involvement is
the most common, further research on this topic, including
longitudinal studies in patients with SSc, is mandatory for a
better understanding of the clinical value of AECA.
However, for long time it has not been determined
prospectively whether SSc autoantibodies are related to the
course and type of microvascular damage detectable by
nailfold capillaroscopy.
LeRoy and Medsger proposed that patients with RP
who had abnormal ﬁndings on NVC and SSc-speciﬁc
autoantibody should be classiﬁed as having early SSc [15].
This set of criteria had not been validated and considered for
long time, until recently.
Finally, Koenig et al. prospectively studied a large cohort
of Raynaud’s patients who were referred to a single centre for
evaluation of RP over a period of 20 years [16].
The objectives were to identify the strongest independent
predictors of progression to deﬁnite SSc, to determine
the type and time course of microvascular damage by
nailfold capillaroscopy and its relationship to major SSc
autoantibodies, and to validate the criteria for early SSc.
Of the 586 patients who were followed up for 3,197
person-years, 74 (12.6%) developed deﬁnite SSc.
In fact, this study validated the criteria of LeRoy by
demonstrating that almost all patients who were to futurely
develop SSc had “early” SSc (Raynaud’s phenomenon plus
a scleroderma pattern on capillaroscopy and/or SSc-speciﬁc
antibodies) at the baseline visit.
Concerning the scleroderma pattern they reported a
characteristic sequence of microvascular damage, starting
with enlarged capillaries (giant capillaries) that identify the
“early” SSc pattern, followed by capillary loss that indicates
the “active” SSc pattern and then by capillary telangiectasias
(neoangiogenesis) that might better characterize the “late”
SSc pattern (Figure 2), from the stadium of “early” SSc until
development of deﬁnite SSc.
DeﬁniteSScwasdiagnosedinclosetemporalrelationship
to capillary loss.
Enlarged capillaries (giant capillaries), capillary loss, and
SSc-speciﬁc autoantibodies independently predicted deﬁnite
SSc.
Interestingly, anti-CENP-B and anti-Th/To antibodies
predicted for the development of giant capillaries; these
autoantibodies andanti RNAPIIIalsopredicted forcapillary
loss. Each autoantibody was associated with a distinct time
course of microvascular damage.
At followup, 79.5% of patients with one of these autoan-
tibodies and abnormal ﬁndings at the baseline nailfold
capillaroscopy examination had developed deﬁnite SSc.
Patients with both baseline predictors were 60 times more
likely to develop deﬁnite SSc.
These data validated the proposed criteria for early SSc.
In conclusion, in the presence of a secondary RP evolving to
deﬁnite SSc, microvascular damage (as assessed by nailfold
capillaroscopy) is dynamic and progressive, and SSc-speciﬁc
autoantibodies are associated with the course and type of
capillary abnormalities.
It was conﬁrmed that the microvascular damage in
secondary RP evolving to deﬁnite SSc is characteristi-
cally sequential, starting with enlarged capillaries (giant
capillaries, “early” SSc pattern) followed by capillary loss
(“active” SSc pattern), and then by capillary telangiectasias
(neoangiogenesis, “late” SSc pattern).
Since new therapeutic agents are being evaluated in
patients with SSc, awareness of this sequence of microvas-
cular damage has potential implications for future trials.











Figure 2: The morphological capillary abnormalities in SSc have been classiﬁed in 3 validated patterns (early, active, and late) of
microangiopathy by NVC analysis.
microangiopathy in “established” SSc disease, by pointing
out the progression of capillary loss and augmentation of
ramiﬁcations in a microangiopathy score [7].
The ﬁnal message is that abnormal ﬁndings on nailfold
capillaroscopy at baseline together with a systemic sclerosis-
speciﬁc autoantibody indicate a very high probability of
developing deﬁnite systemic sclerosis whereas their absence
excludes this outcome [17]. In SSc patients awareness of
this sequence of microvascular damage and SS-associated
autoantibodies has potential implications for future thera-
peutical trials.
For example, in trials of novel angiogenic, vasculogenic,
or ﬁbrosis-modulating agents, it would appear realistic to
select SSc patients at a uniform stage of microvascular
damage and with similar SSc-speciﬁc autoantibodies and
eventually to evaluate such damage longitudinally by NVC
to assess response to treatment.
3.SkinDigitalUlcers andNVC
Skin DUs represent one of the most frequent clinical
manifestations of microangiopathy in patients with SSc
(Figure 3)[ 18].
Ontheotherhand,adecreasednumberofcapillaryloops
should be considered highly speciﬁc for advanced RP, and
it has been estimated that the number of normal capillaries
may be reduced to just 20% in patients with active SSc. Skin
DUs seem to be associated with the “late” NVC pattern,
characterized by avascular areas (severe capillary loss).
Recently, using a semiquantitative score that highlights
the importance of the number of capillaries, an association
wasreportedbetweenadvancedstagesofcapillaryloss(mean
score class 2 and 3) and digital trophic lesions in 49%
of patients with SSc [19]. Also, loss of capillaries may be
relevant in determining tissue hypoxia, and, in patients
with recent onset of RP, the appearance of rapidly pro-
gressive capillary loss may represent the ﬁrst capillaroscopic
evidence of severe SSc with destruction of microvessels
[20].
The extensive disappearance of capillaries may generate
large avascular areas giving a “desert-like” appearance to
the nailfold bed, and progressive loss of capillaries has been
associated with more extensive skin involvement (as well as
diﬀuse SSc) and a poor prognosis.
As a consequence, the early detection of SSc patients who
are at high risk of developing DU could allow preventive
treatment of these complications with reduction of morbid-
ity and social costs.
Very recently, it was found, in 130SSc patients examined
at entry and after 20 months of follow-up, that the diﬀuse
cutaneous formof SSc with avascularareas on capillaroscopy
represented,amongotherfactors(e.g.,increasedinterleukin-
6) the major risk factor for DU development [21].
A previous study showed that, patients with late SSc
pattern at NVC showed an increased risk to have an active
disease (odds ratio (OR) 3.50; 95% conﬁdence interval (CI)
1.31–9.39) and to present skin DU (OR 5.74; 95% CI 2.08–
15.89) [2].4 International Journal of Rheumatology
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Figure 3:Classicalskindigitalulcerinapatientaﬀectedbysystemic
sclerosis.
Another recent investigation showed that a quantitative
capillaroscopic score was suggested highly predictive of the
development of new skin DU within 3 months after NVC
[22]. The predictive value of this index still needs to be
conﬁrmed in a validation study.
A clinical history of multiple skin DU is the most helpful
predictorandindicatorforpreventivetherapy,andthelossof
capillary as assessed at NVC has been found the best possible
NVC predictive marker to be considered.
However, the routine use of NVC now seems a possible
predictive tool to enable the early detection of patients at a
highriskofdevelopingskinDU[1].Inthisregard,atpresent,
the cost/eﬀectiveness ratio for the therapy of SSc skin DU
is very unfavourable, and strategies for their treatment or
prevention are under debate [2].
4. Pulmonary Arterial Hypertensionand NVC
SScisthemainconnectivetissuediseaseassociatedwithPAH
and PAH is estimated to aﬀect 12% of SSc patients, being the
leading cause of death in this disease [23].
Structural changes in the systemic microcirculation,
consisting of a reduction of capillary density and widening
of the capillaries, are considered an hallmark of SSc.
It is now clear that the severity of this microvascular
damage as assessed by NVC diﬀers between patients with SSc
and PAH (SSc-PAH) and those with SSc without PAH (SSc-
non-PAH) and correlates with pulmonary haemodynamic
parameters.
Interestingly, when compared to healthy controls, the
same is true for patients with idiopathic PAH, a condition
not known to be characterized by systemic microvascular
changes [24].
A recent study suggests that capillary density reduction is
a marker of the presence and severity of PAH [24].
A few studies have investigated nailfold capillary patterns
in patients with SSc-PAH, with only one study including
patients with idiopathic PAH. Two studies used echocar-
diography and/or right heart catheterisation to conﬁrm the
diagnosis of PAH. One of these, by Ong et al., found a
signiﬁcant reduction of capillary density in eight patients
with SSc-PAH in comparison with 12 patients with SSc-non-
PAH [25]. Pulmonary haemodynamic parameters were not
reported in the study by Ong.
The other study, by Greidinger et al. using capillary
density and qualitative scoring of nailfold patterns, found no
diﬀerences in capillary patterns between eight patients with
SSc-non-PAH and seven with SSc-PAH, but capillary density
in these groups was not reported [26].
A third study, by Ohtsuka et al. using only right heart
catheterisationtodiagnoseandexcludethediagnosisofPAH,
showed a signiﬁcant diﬀerence in semiquantitative scoring
of nailfold patterns between SSc-non-PAH and SSc–PAH
patients, but, again, capillary density was not assessed in this
study [27].
Practically, only one of these studies included patients
with idiopathic PAH and reported no diﬀerences in capillary
density and capillary patterns between 13 healthy controls
and 37 patients with idiopathic PAH.
There is, however, more recent evidence of a reduction
of capillary density in both SSc-PAH and, albeit to a milder
extent, in idiopathic PAH [24].
The explanation for a reduction in capillary density
may not be the same for the two disorders. In SSc it is
generally presumed that structural changes in the systemic
(micro)circulation precede changes in the pulmonary circu-
lation, as systemic microvascular changes may precede the
development of SSc by many years.
Therefore, NVC abnormalities might also reﬂect what is
going on in the pulmonary circulation. This may not be true
for all capillary abnormalities, because most patients with
SSc demonstrate nailfold capillary abnormalities whereas
only a minority develop PAH. Recent data conﬁrm that only
capillary density is associated with the presence of PAH and
is a marker of disease severity in SSc [24].
A further suggested explanation for the more pro-
nounced capillary reduction in SSc-PAH could be that PAH
itself ampliﬁes the reduction of capillary density already
present in SSc.
However, Houben et al. recently observed an increase
rather than a decrease of nailfold capillary density in patients
with heart failure [28].
The observation that circulating plasma levels of
endothelin1 (ET-1) are raised in patients with PAH and
that ET-1 production is increased in the pulmonary tissue
of aﬀected individuals makes this vasoconstrictor a particu-
larly interesting target for therapeutic intervention in PAH
[29].
Clinical trials with ET receptor antagonists have clearly
shown that such antagonists provide symptomatic beneﬁt in
patients with PAH, thereby proving the clinical relevance of
the endothelin system as a therapeutic target with optimised
use of selective ETA or nonselective ETA/ETB blockade.
As matter of fact the highest serum ET-1 levels are found
in SSc with late NVC pattern and visceral involvement [30].
Recent therapeutical examples of clinical trials with NVC
as measure of outcome and conclusions are presented.
Very recent studies represent examples of clinical trials in
which NVC has been successfully included as a measure of
treatment outcome.International Journal of Rheumatology 5
The objective of one study was to evaluate NVC pattern
changes in SSc patients treated regularly on cyclic basis with
iloprost and to ﬁnd associations with clinical, serologic, and
pharmacological variables [31].
Forty-nine patients aﬀected by SSc underwent two NCV
analyses at 3 years apart from each other. Six patients showed
an amelioration of NVC abnormalities who changed from
active to early pattern; ﬁve of these cases (83.3%) had been
given cyclophosphamide therapy and the remaining case
methotrexate plus azathioprine.
Cyclophosphamide administration was signiﬁcantly
associated with regression of the NVC pattern (P<. 001).
Interestingly, none of the SSc patients who received cyclo-
phosphamide demonstrated worsening of the microvascular
lesions; the progression of NVC pattern was inversely
correlated to cyclophosphamide treatment (P = .02).
Therefore, cyclophosphamide treatment demonstrated
to be eﬀective in modulating the SSc microvascular damage
as directly observed and monitorized by NVC.
In another study cyclophosphamide treatment showed
to be eﬀective for SSc microvascular damage as directly
observed by rapid improvement of the NVC pattern [32].
Conﬁrmation of the trend was obtained by a further
studyonautologousstemcelltransplantationthatconﬁrmed
a signiﬁcant regression of the NVC pattern together with the
improvement of the clinical conditions [33].
In conclusion, to the question if capillaroscopy (NVC)
may represent in SSc an outcome measure for clinical
trials on the peripheral vasculopathy, based on the growing
evidences and our detailed studies, the answer is positive.
Early recent therapeutic trials in SSc are conﬁrming this
role, and the experience is growing rapidly [34].
To deﬁnitely establish its role as an outcome measure
two requirements still need to be fulﬁlled. First, large
multicentric and longitudinal and randomized controlled
trials(certainlyinestablishingitsroleasanoutcomemeasure
in therapeutical trials) are needed. Second, multicentric
reliability in scoring systems is warranted.
Recently, a ﬁrst step in assessing reliability has been
takenthroughdemonstrationofreliabilitybothinqualitative
and semiquantitative assessment of nailfold images of SSc
patients in a bicentre setting [5].
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